Enzo Biochem announced that it has entered into an agreement with MultiGEN Diagnostics Inc, of San Diego for exclusive rights to market MultiGEN’s unique diagnostic tests based on multiplex DNA sequencing, in the state of New York.
In addition, Enzo has been granted marketing rights for other non-exclusive territories in United States.
“These particular tests utilize true state of the art technology and offer physicians serving women highly accurate and convenient options for improved patient service.”
Enzo will validate and seek approval of an Antenatal Infectious Disease panel as well as a thrombophilia panel pursuant to New York, New Jersey and CLIA [Clinical Laboratory Improvement Act] requirements, in addition to marketing, and securing third party reimbursement for the test. Terms were not disclosed. Enzo said that subject to regulatory and reimbursement approval, among others, it hopes to make the test available in the second half of 2010.
The tests bolster Enzo’s already strong portfolio of women’s health diagnostics. The antenatal panel allows for simultaneous identification of certain bacterial viral or fungal pathogens in a single convenient specimen. Additionally, the thrombophilia panel detects multiple mutations that can diagnose genetic predisposition to blood clotting.
“In our continuing mission to develop and offer cutting edge esoteric tests that provide our clients the best diagnostic tools that exist we are pleased to announce this alliance with MultiGEN,” said Kevin Krenitsky, MD, President of Enzo Labs. “These particular tests utilize true state of the art technology and offer physicians serving women highly accurate and convenient options for improved patient service.”
“Enzo Clinical Labs innovative capabilities in developing tests in New York State, combined with their existing commitment to offer world class diagnostics in the women’s health arena make them the perfect partner for us,” said T. Vinayagamoorthy, PhD, Founder and President of MultiGEN Diagnostics. “MultiGEN has developed a truly novel next generation multiplex sequencing technology that advances the accuracy and utility of these diagnostic tests and we are very pleased to begin offering them in Enzo’s highly populated geographical region. Early feedback in the test markets from the physician community has been extremely positive.”
Source: Enzo Biochem